An observational study in Osteoarthritis and Rheumatoid Arthritis, sponsored by Stryker Japan K.K.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-09-17.
Sponsored by Stryker Japan K.K. · Observational
The purpose of this study is to evaluate the range of motion (ROM), mid-flexion stability (gap balance), and implant position (size and angle) for the Scorpio NRG device. Relationship between these parameters and clinical outcomes will be evaluated as well as the importance of rotational tolerance. It is expected that the Scorpio NRG will have good clinical outcomes and perform the same or better than other total knee implants.
4,397 studies on the registry are indexed under Osteoarthritis; 581 are open to participants now.
This study's enrollment of 150 is above the median of 100 across 790 observational studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Stryker Japan K.K. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient who has diagnosis of osteoarthritis or rheumatoid arthritis.
Exclusion Criteria:
Device: Scorpio NRG posterior stabilized (PS)
Change in Range of motion(ROM)
Time frame: Pre-operation, intraoperative, 6 months and 1 year after surgery
Change in Japanese Orthopaedics Association (JOA) score,
Time frame: Pre-operation, intraoperative, 6 months and 1 year after surgery
Change in Knee Society Score (KSS)
Time frame: Pre-operation, intraoperative, 6 months and 1 year after surgery
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stryker Japan K.K.